Paula Morales

Madrid, MD 28006, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain.

PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain.

Journal: Neuropharmacology

Published: January 13, 2026

Structural and functional dissection of the WH2/DAD motif of INF2, a formin linked to human inherited degenerative disorders.

Structural and functional dissection of the WH2/DAD motif of INF2, a formin linked to human inherited degenerative disorders.

Journal: The FEBS journal

Published: March 29, 2025

Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer.

Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer.

Journal: Biomolecules

Published: September 25, 2024

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling.

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling.

Journal: Pharmacological research

Published: May 11, 2024

Progress on the development of Class A GPCR-biased ligands.

Progress on the development of Class A GPCR-biased ligands.

Journal: British journal of pharmacology

Published: December 11, 2023

Editorial: New approaches for the discovery of GPCR ligands.

Editorial: New approaches for the discovery of GPCR ligands.

Journal: Frontiers in endocrinology

Published: August 04, 2023

Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair.

Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair.

Journal: NeuroImmune pharmacology and therapeutics

Published: July 28, 2023

The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls.

The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls.

Journal: EMBO molecular medicine

Published: July 24, 2023

Editorial: Cannabinoids as potential treatment for neurological diseases.

Editorial: Cannabinoids as potential treatment for neurological diseases.

Journal: Frontiers in neuroscience

Published: November 25, 2022

Viewpoint on the Second Transatlantic GPCR Symposium for Early Career Investigators.

Viewpoint on the Second Transatlantic GPCR Symposium for Early Career Investigators.

Journal: ACS pharmacology & translational science

Published: November 17, 2022

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship.

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship.

Journal: ACS medicinal chemistry letters

Published: July 14, 2022

The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.

The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.

Journal: Life sciences

Published: February 26, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026